BiondVax Pharmaceuticals Ltd. is developing innovative peptide based vaccines conceptualized and invented by Prof. Ruth Arnon at the Weizmann Institute, Israel. The first application is a universal multi-season/multi-strain influenza vaccine that provides long-term protection against a vast majority of flu viruses. Current influenza vaccines are strain dependent and do not confer protection against emerging strains. The peptide-based approach utilizes the conserved components from the different viral proteins that are common to many influenza viruses and use them for vaccination so that a single formulation is efficient against most of flu viruses. Pre clinical studies demonstrated the protective effect against many influenza strains including the highly pathogenic avian influenza H5N1. Currently, the company is in Phase I clinical trial.
BiondVax Pharmaceuticals, a publicly-traded company (TASE: BNDX) located in the Weizmann Science Park in Ness-Ziona (Israel), is dedicated to the development of a novel Universal Influenza Vaccine. BiondVax's Universal Flu Vaccine is based on research carried out over a period of 20 years by Professor Ruth Arnon, who heads the company's Scientific Advisory Board.
Visit www.biondvax.com for more information.